Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

NeuroSearch A/S22 enrolled

Overview

The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Parkinson's Disease Tolerability

Interventions

ACR325DRUG

Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

PlaceboDRUG

Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

Eligibility

Sex: ALLMin age: 30 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of idiopathic Parkinson"s disease according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria * Levodopa induced dyskinesia Exclusion Criteria: * Previous surgery for Parkinson's disease * Any current or history of heart condition or increased pro-arrhythmic risk * Severe or ongoing unstable medical condition

Locations (2)

Paracelsus-Elena-Klinik

Kassel, Hesse, Germany

Klinik für Neurologie, Philipps-Universität Marburg

Marburg, Hesse, Germany

Outcomes

Primary Outcomes

Safety and tolerability

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.